Cost analysis in thyroid cancer clinical trials: Toward value-based oncology care.
[BACKGROUND] Clinical trials are crucial in advancing novel therapies for thyroid cancer.
APA
Rogers JL, Henostroza S, et al. (2026). Cost analysis in thyroid cancer clinical trials: Toward value-based oncology care.. American journal of surgery, 252, 116772. https://doi.org/10.1016/j.amjsurg.2025.116772
MLA
Rogers JL, et al.. "Cost analysis in thyroid cancer clinical trials: Toward value-based oncology care.." American journal of surgery, vol. 252, 2026, pp. 116772.
PMID
41386062
Abstract
[BACKGROUND] Clinical trials are crucial in advancing novel therapies for thyroid cancer. Given the increased cost of modern healthcare, cost considerations in clinical trials are important yet remain under-reported.
[METHODS] A search of ClinicalTrials.gov identified thyroid cancer studies including cost in the trial description or as an outcome. Data collected included trial information, cost outcomes, and cost-effectiveness analyses.
[RESULTS] Among 46 thyroid cancer-focused clinical trials, only 28 (60.8 %) mentioned cost in any capacity, of which 21 (75 %) included cost outcomes and 7 (25 %) included cost-effectiveness analyses. Overall, cost was a primary outcome in 1 (2.2 %) trial, secondary outcome in 20 (43.5 %) trials, and exploratory outcome in 7 (15.2 %) trials.
[CONCLUSION] The inclusion of cost analysis in thyroid cancer clinical trials is limited. Given rising cost pressures in modern healthcare systems, the low prevalence of cost endpoints and cost-effectiveness analyses underscores the need for increased awareness and investment in this domain.
[METHODS] A search of ClinicalTrials.gov identified thyroid cancer studies including cost in the trial description or as an outcome. Data collected included trial information, cost outcomes, and cost-effectiveness analyses.
[RESULTS] Among 46 thyroid cancer-focused clinical trials, only 28 (60.8 %) mentioned cost in any capacity, of which 21 (75 %) included cost outcomes and 7 (25 %) included cost-effectiveness analyses. Overall, cost was a primary outcome in 1 (2.2 %) trial, secondary outcome in 20 (43.5 %) trials, and exploratory outcome in 7 (15.2 %) trials.
[CONCLUSION] The inclusion of cost analysis in thyroid cancer clinical trials is limited. Given rising cost pressures in modern healthcare systems, the low prevalence of cost endpoints and cost-effectiveness analyses underscores the need for increased awareness and investment in this domain.
MeSH Terms
Humans; Clinical Trials as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Thyroid Neoplasms